CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SCB-2019 with CpG 1018 adjuvant plus Alum adjuvantWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2150 SCB-2019 with AS03 adjuvant Wiki 1.00
drug2149 SCB-2019 Wiki 1.00
drug3018 survey Wiki 0.41

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.

This is a randomized, double blind, placebo controlled, first-in-human (FIH) study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects. Each study vaccine dose level will be evaluated with and without adjuvant.

NCT04405908 COVID-19 Biological: SCB-2019 Biological: SCB-2019 with AS03 adjuvant Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant

Primary Outcomes

Measure: Incidence of solicited adverse events (AEs) after vaccination

Time: 7 days after the first or second vaccination.

Measure: Incidence of unsolicited AEs after vaccination

Time: Day 1 to Day 50

Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

Measure: Immunogenicity(Anti-SCB-2019 Antibody Titers)

Time: Day 1 to Day 184

Measure: Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)

Time: Day 1 to Day 184

Secondary Outcomes

Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

Measure: Immunogenicity( serum anti SARS-CoV-2 neutralizing antibody titers (ACE2 receptor-based) )

Time: Day 1 to Day 184

Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

Measure: Immunogenicity(serum anti SARS-CoV-2 neutralizing antibody titers (cell based) )

Time: Day 1 to Day 184

Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

Measure: Immunogenicity(serum anti SARS-CoV-2 whole virus antibody titers)

Time: Day 1 to Day 184

Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).

Measure: Antibody kinetics of each SCB 2019 vaccine formulation after first and second doses

Time: Day 1 to Day 184


No related HPO nodes (Using clinical trials)